Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Greg Palmer

Dermatology Aurora, IN Medical Doctor

NPI 1831194133 CMS profile 386821

107 Bridgeway St, Suite 201, Aurora, IN 47001

Open in the dashboard

General payments

$252

15 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Greg Palmer of Aurora, IN is reported in the CMS Open Payments database as having received $252 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 17th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54 3
2024 General $69 4
2023 General $71 4
2022 General $43 3
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Greg Palmer
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Greg Palmer were reported at $54. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Greg Palmer Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $15 $377 $108–$1,108 $132
2022 $43 $514 $143–$1,391 $149
2023 $71 $607 $159–$1,674 $160
2024 $69 $751 $204–$1,903 $164
2025 $54 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $229 14 payments
  2. Krystal Biotech Inc $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $252 15 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $183 11 payments
  2. SKYRIZI Immunology $32 2 payments
  3. VYJUVEK $22 1 payment
  4. HUMIRA $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

196

Median for Dermatology: 534

Drug cost

$53,606

Median for Dermatology: $67,151

Branded share of claims

6.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 13 $48,351
Fluorouracil Generic 16 $1,315
Metronidazole Generic 23 $1,162
Clindamycin Phosphate Generic 14 $794
Triamcinolone Acetonide Generic 50 $568
Clobetasol Propionate Generic 23 $561
Ketoconazole Generic 44 $430
Fluocinonide Generic 13 $426

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$23,487

Medicare's payments for the services billed

Medicare patients

210

Average age 74

Services billed

488

64 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 42%
Ischemic heart disease 32%
Diabetes 25%
Atrial fibrillation 18%
Chronic kidney disease 18%
Cancer 16%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record